SIGNAL Underwriting has developed new products while upgrading existing ones to better serve its broker partners.
The company’s new offerings include clinical trial liability, non-profits, product recall, and technology errors and omissions (E&O). In addition, SIGNAL enhanced its directors and officers (D&O) liability and manufacturing and wholesale policies.
“We’re excited to announce that now all our products are written in-house – giving you direct access to the expert behind your coverage for any questions or support,” said chief executive and class underwriter Alexander Blair-Johns (pictured), addressing the firm’s broker partners in an update.
SIGNAL’s new standalone clinical trial liability policy is tailored for companies in the pharmaceutical, biopharmaceutical, nutraceutical, and medical device sectors. Coverage includes no fault compensation for human clinical trials and medical monitoring expenses.
The new non-profits package offers comprehensive cover including general liability, non-profit D&O, E&O, and property insurance. It is designed for a variety of organizations such as animal and environmental groups, arts and culture institutions, and trade associations.
Meanwhile, specifically targeting the food and beverage industry, as well as supplements, over-the-counter medication, and low-risk pharmaceuticals, SIGNAL’s product recall policy offers coverage up to $10 million. Clients also receive complimentary access to RQA crisis consultants for added support.
The technology E&O product is aimed at IT consultants, website designers, and those involved in hardware sales, installation, and maintenance, as well as software development (excluding financial software). The policy provides E&O limits up to $2 million.
As for the improvements, SIGNAL offers private and excess D&O coverage with limits up to $5 million, covering a wide range of industries.
Additionally, the manufacturing & wholesale policy offers global coverage. The package includes a manufacturing E&O endorsement for contract manufacturers, as well as an available product recall endorsement.
What do you think about this story? Share your thoughts in the comments below.